Olezarsen significantly remodels Lp(a) particles by reducing their TG and cholesterol content, without affecting Lp(a) concentration, according to results from a Phase 2 dose ranging study of the apoC3 inhibitor recently approved in the USA for use in adults with familial chylomicronaemia syndrome (FCS).
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.